BBOT

BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT

9.79 USD
+0.14
1.45%
At close Aug 13, 4:00 PM EDT
After hours
9.96
+0.17
1.74%
1 day
1.45%
5 days
4.93%
1 month
-8.25%
3 months
-9.77%
6 months
-8.50%
Year to date
-10.92%
1 year
-5.87%
5 years
-3.93%
10 years
-3.93%
Financials Shell Companies
0
Funds holding %
of 7,338 funds
–
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

8% more capital invested

Capital invested by funds: $173M [Q4 2024] → $186M (+$13.6M) [Q1 2025]

0.22% more ownership

Funds ownership: 86.97% [Q4 2024] → 87.19% (+0.22%) [Q1 2025]

3% less funds holding

Funds holding: 32 [Q4 2024] → 31 (-1) [Q1 2025]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for BBOT.

See Analyst Rankings

Financial journalist opinion

Neutral
GlobeNewsWire
2 days ago
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025. Closed concurrent $261 million private investment in public equity (“PIPE”), led by Cormorant.
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
See News Rankings
Charts implemented using Lightweight Charts™